GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope : Critical Reasoning (CR)

P

rxb266

Manager

Joined: 30 Nov 2018

Posts: 202

Own Kudos [?]: 149 [1]

Given Kudos: 79

Location: India

Concentration: Strategy, Marketing

Schools: HEC MiM '21 HEC Sept'22 Intake ISB '24 Rotman '24

GPA: 4

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 02:53

1

Kudos

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries.

Conclusion: In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax. Incorrect as it does not weaken our conclusion.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff. Incorrect as it does not weaken our conclusion.

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently. Voila !! If the partner at some point may manufacture independently then it hurts the part of the argument written in bold.

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower. Incorrect as it does not weaken our conclusion.

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol. Incorrect as it does not weaken our conclusion.

IMO Option C

G

akash2703

Manager

Joined: 13 Mar 2018

Posts: 103

Own Kudos [?]: 96 [0]

Given Kudos: 37

Location: United States (CA)

GPA: 3.78

WE:Consulting (Consulting)

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 03:33

Imo E

DTI is looking for partners in underdeveloped countries so that these partners can hire hire cheap labor and the manufacturing cost be reduced, making the cost of vaccine affordable for the consumers.
We have to weaken the implementation of this plan.

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.
It gives more reason that DTI will get a partner in underdeveloped countries.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.
Irrelevant. Will it impact any of the partner's position? we don't know.

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.
As long as the the company is getting a partner at present, the plan is a success.

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.
Do we need to hire a staff from DTT for the partner to manufacture the vaccine? We don't know. In fact the original objective was to hire labors from the under developed countries themselves. This statement is strengthening the argument.

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.
Since DTI has a competitor for some other vaccine. The partners may choose Gardisol for their profit. This statement weakens the success of the plan.

GoalEver

Intern

Joined: 11 Feb 2019

Posts: 6

Own Kudos [?]: 3 [0]

Given Kudos: 2

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 04:19

Answer C.

"Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?"

We are looking for a proposition that raises doubt about the success of the plan of management of DTI.

What are they planning to do? => They are looking for a partner with facilities in underdevelopped country to manufacture vaccine on their behalf for underdevelopped market.
But since the labor cost is the one in cause here, the labor cost in underdevelopped country needs to be qualified for the task. Therefore a transfer of knowledge will be needed with the risks assiociated to that.

So Answer C for me.

P

manish1708

Manager

Joined: 10 Aug 2016

Posts: 145

Own Kudos [?]: 269 [1]

Given Kudos: 61

Location: India

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 04:47

1

Kudos

Answer: C

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries. In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax. --> Incorrect. This rather strengthens. DTI can collaborate with these companies in underdeveloped countries to produce required vaccine thereby extending the market in underdeveloped countries.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff. --> Incorrect. Who operates current operations is out of scope.

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently. --> Correct. If the partner starts manufacturing independently then DTI will be back to square one looking for another partner with DTI's market share taking a hit.

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower. --> Incorrect. We do not know if partner requires expert staff from DTI or not. Out of scope.

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol. --> Incorrect. Competitor or DTI, another vaccine are out of scope.

L

pintukr

VP

Joined: 03 Jul 2022

Posts: 1238

Own Kudos [?]: 799 [0]

Given Kudos: 21

GMAT 1: 680 Q49 V34

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 06:05

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries. In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

Weakener required,,,

Any factor impinging on sales of the vaccines manufactured by Fluvax will serve to raise doubt about the success of the plan of the management of DTI Biotechnology Inc

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.
It is a strengthener..If numerous companies available in underdeveloped countries, vaccine manufacture at cheaper costs easily possible

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.
Hiring at lower labour costs in underdeveloped countries will enable replacement of DTI's own staff, and thus reduce overall labour costs..hence, vaccines can be manufactured at cheaper costs...again a strengthener !!

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.
A futuristic prediction..while there is a need to evaluate the success of the plan in present context..Hence, out of scope

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.
Partner not able to attract experts for manufacture of vaccines owing to low salaries will in turn mar the plans related to manufacturing vaccines at cheaper costs

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.
Role of competitor will mildly impact by hiring of labour at comparatively higher labor costs..No data presented in the stimulus..hence, may or may not lead to success of the plan

(D) is the correct option

P

av1901

Senior Manager

Joined: 28 May 2022

Status:Dreaming and Working

Affiliations: None

Posts: 478

Own Kudos [?]: 380 [0]

Given Kudos: 83

WE:Brand Management (Manufacturing)

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 06:11

Bunuel wrote:

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries. In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.

This question was provided by GMAT Club
for the GMAT Club World Cup Competition

Compete, Get Better, Win prizes and more

Thank you sayantanc2k for the question!!!

Fluvax, being developed in developed countries with expensive labor, cannot be made available due to price in other countries. So company is searching for partners in other countries who can manufacture on behalf of DTI in those countries using the cheap labor. What could make their plan not succeed?
Let us examine the options:

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.

Actually strengthens the point, more companies means more options means easier to find. ELIMINATE

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.

Ok, just some information that in no way raises doubts or otherwise

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.

Yes, seems plausible but their plan is to find partners and have them develop the vaccine, not worrying about partners stealing their idea and building for themselves. Their plan is present, this is future, and that too, possible future (indicated by may). ELIMINATE

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.

YES! DTI know how to do it, if partner cannot hire from them due to wage issues, they wont be able to manufacture the vaccine thus plan will fail. ANSWER

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.

Irrelevant. ELIMINATE

Answer - D

G

neetib

Manager

Joined: 27 Jan 2017

Posts: 106

Own Kudos [?]: 107 [1]

Given Kudos: 483

Location: India

Schools: ISB '20 Harvard '24 IESE '24 LBS '24 NUS

GMAT 1: 640 Q46 V34

GMAT 2: 650 Q46 V34

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 06:40

1

Kudos

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.This is supporting the conclusion.OUT

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.Not creating any doubt .OUT

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.Correct

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.OUT

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.Out of scope .OUT

OA:C

G

Fido10

Manager

Joined: 12 Aug 2020

Posts: 100

Own Kudos [?]: 100 [0]

Given Kudos: 295

Location: Morocco

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 06:48

The plan of the company is : In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

What could makes this plan not successful

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.
the fact of existing other companies developping the vaccine in other places is irrelevant to evaluate the successfulness of the plan of the company, Wrong answer
B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.
From this info, nothing could be said whether it the operations cannot be performed from another location, ireelavant,
C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.
if the partner manufactures independently, this strenghten the conclusion, Wrong answer
D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.
This is the correct answer, because if all the prerequisites are Ok, if the company, does not have the human resources qualified to perform the vaccine production, its plan to transporting the plants into an underdeveloped country, could make the plan unseccessful , and excatly that this answer choice is telling, that in underdeveloped country, the salaries are much lower
E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.
anoher competitor searching for a partner in the same location as the company producing the vaccines is completely irrelevant to evaluate the plan, Wrong answer

P

Vatsal7794

ISB & IIM Moderator

Joined: 17 Mar 2021

Posts: 289

Own Kudos [?]: 121 [1]

Given Kudos: 123

Location: India

Schools: IIMB EPGP'25 Schulich Sep'24 intake Fisher '26 ISB '25

GMAT 1: 660 Q44 V36

GPA: 3.5

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 07:42

1

Kudos

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries. In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.
out of scope

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.
Does not raise any doubt

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.
This weakens the staement

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.
Does not raise any doubt

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.
Does not raise any doubt

Answer is C

G

Berdiyor

Manager

Joined: 02 Feb 2019

Posts: 86

Own Kudos [?]: 84 [1]

Given Kudos: 14

Location: Uzbekistan

Schools: Questrom '26 (A$$$)

GMAT 1: 640 Q50 V25

GMAT 2: 670 Q51 V28

GPA: 3.4

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 07:59

1

Kudos

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries. In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.

The answer is C

L

Bunuel

Math Expert

Joined: 02 Sep 2009

Posts: 92952

Own Kudos [?]: 619329 [0]

Given Kudos: 81611

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

20 Jul 2022, 08:03

Expert Reply

Bunuel wrote:

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries. In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.

D. The partner cannot attract any expert staff from DTI who are currently involved in manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol.

This question was provided by GMAT Club
for the GMAT Club World Cup Competition

Compete, Get Better, Win prizes and more

Thank you sayantanc2k for the question!!!

Official Explanation is pinned as BEST Reply HERE.

G

sayantanc2k

CR Moderator

Joined: 14 Dec 2013

Posts: 2413

Own Kudos [?]: 15266 [0]

Given Kudos: 26

Location: Germany

Schools:

GMAT 1: 780 Q50 V47

WE:Corporate Finance (Pharmaceuticals and Biotech)

Send PM

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

22 Jul 2022, 06:29

Expert Reply

Iotaa wrote:

Bunuel wrote:

The vaccine Fluvax has been developed by the company DTI Biotechnology Inc. Currently the vaccine is manufactured at the company’s own facilities at Vaccitown located in a developed country. However, as in other towns in developed countries, the labor costs at Vaccitown are pretty high, making the vaccine unaffordable for many underdeveloped countries. In order to extend the market of Fluvax in underdeveloped countries, the management of DTI Biotechnology is searching for partners in underdeveloped countries, who can manufacture the vaccine on behalf of DTI at cheaper costs for the local market.

Which of the following, if true, most seriously raises doubt about the success of the plan of the management of DTI i?

A. There are numerous companies in underdeveloped countries, who are capable of manufacturing vaccines such as Fluvax.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff.

C. Manufacturing at a partner’s facility requires transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently.

D. The partner cannot attract any expert staff from DTI who are currently involved in the manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower.

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardasil.

This question was provided by GMAT Club
for the GMAT Club World Cup Competition

Compete, Get Better, Win prizes and more

Thank you sayantanc2k for the question!!!

Select an option which raises doubt about the success of the plan of the management of DTI of Expanding in underdeveloped nations and selling in the local market at a cheaper price.

A. There are numerous companies in underdeveloped countries, that are capable of manufacturing vaccines such as Fluvax: The market is already occupied. Even after expansion to an underdeveloped nation, DTI may not be able to sell in the local market. Hold this option.

B. Currently all of DTI’s operations are handled in-house by DTI’s own staff : I rrelavant. Reject

C. Manufacturing at a partner’s facility requires the transfer of knowledge to the partner that bears the risk that the partner at some point may manufacture independently. Out of Scope. Reject

D. The partner cannot attract any expert staff from DTI who are currently involved in the manufacturing of Fluvax, because the salaries in underdeveloped countries are much lower: Out of Scope. Reject

E. A competitor of DTI for another vaccine called Gardisol targeted at a different disease, is also searching for partners in underdeveloped countries to capture the market of Gardisol: Out of Scope. Reject

Hence A is the correct answer

I presume, you did not realise the difference between vaccine developers and vaccine manufacturers.

gmatclubot

Re: GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope [#permalink]

22 Jul 2022, 06:29

GMAT Critical Reasoning (CR) Questions

GMAT Club World Cup 2022 (DAY 7): The vaccine Fluvax has been develope